Literature DB >> 6822361

Two pathogenetic types of endometrial carcinoma.

J V Bokhman.   

Abstract

The author presents a hypothesis that the complex of endocrine and metabolic disturbances arising long before the development of endometrial carcinoma determines the biological peculiarities of the tumor, its clinical course, and the prognosis of the disease. On the basis of a prospective study of 366 patients with endometrial carcinoma, the author postulates that there are two different pathogenetic types of endometrial carcinoma. The first pathogenetic type of the disease arises in women with obesity, hyperlipidemia, and signs of hyperestrogenism: anovulatory uterine bleeding, infertility, late onset of the menopause, and hyperplasia of the stroma of the ovaries and endometrium. The second pathogenetic type of the disease arises in women who have no signs stated above or these signs are not clearly defined. The frequency of the first pathogenetic type in the studied group of women was 65%, whereas the frequency of the second type was 35%. The peculiarities outlined above which are characteristic of the first pathogenetic type of the disease determine the development of highly and moderately differentiated tumors (82.3% G1 and G2), superficial invasion of the myometrium (69.4%), high sensitivity to progestogens (80.2%), and favorable prognosis (85.6% 5-year survival rate). In patients who have the second pathogenetic type of endometrial cancer when endocrine and metabolic disturbances are absent or occult, poorly differentiated tumors arise (62.5% G3), a tendency to deep invasion of tumor into the myometrium is observed (65.7%); high frequency of metastatic spread into the pelvic lymph nodes (27.8%); decrease of sensitivity to progestogens (42.5%); and doubtful prognosis (58.8% 5-year survival rate) are noted.

Entities:  

Mesh:

Year:  1983        PMID: 6822361     DOI: 10.1016/0090-8258(83)90111-7

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  571 in total

Review 1.  Drug therapy for gynaecological cancer in older women.

Authors:  R E van Rijswijk; J B Vermorken
Journal:  Drugs Aging       Date:  2000-07       Impact factor: 3.923

Review 2.  Development of targeted therapy in uterine serous carcinoma, a biologically aggressive variant of endometrial cancer.

Authors:  Karim S El-Sahwi; Peter E Schwartz; Alessandro D Santin
Journal:  Expert Rev Anticancer Ther       Date:  2012-01       Impact factor: 4.512

3.  High levels of Nrf2 determine chemoresistance in type II endometrial cancer.

Authors:  Tao Jiang; Ning Chen; Fei Zhao; Xiao-Jun Wang; Beihua Kong; Wenxin Zheng; Donna D Zhang
Journal:  Cancer Res       Date:  2010-06-08       Impact factor: 12.701

4.  Rapamycin inhibits cell proliferation in type I and type II endometrial carcinomas: a search for biomarkers of sensitivity to treatment.

Authors:  Victoria L Bae-Jump; Chunxiao Zhou; John F Boggess; Young E Whang; Lisa Barroilhet; Paola A Gehrig
Journal:  Gynecol Oncol       Date:  2010-09-21       Impact factor: 5.482

Review 5.  Non-Coding RNAs in Endometrial Physiopathology.

Authors:  Alessandro La Ferlita; Rosalia Battaglia; Francesca Andronico; Salvatore Caruso; Antonio Cianci; Michele Purrello; Cinzia Di Pietro
Journal:  Int J Mol Sci       Date:  2018-07-20       Impact factor: 5.923

6.  Is there a benefit of lymphadenectomy for overall and recurrence-free survival in type I FIGO IB G1-2 endometrial carcinoma? A retrospective population-based cohort analysis.

Authors:  Thomas Papathemelis; Dunja Hassas; Michael Gerken; Monika Klinkhammer-Schalke; Anton Scharl; Michael P Lux; Mathias W Beckmann; Sophia Scharl
Journal:  J Cancer Res Clin Oncol       Date:  2018-07-23       Impact factor: 4.553

7.  Association Between Single Nucleotide Polymorphism +276G > T (rs1501299) in ADIPOQ and Endometrial Cancer.

Authors:  Jan Bieńkiewicz; Beata Smolarz; Andrzej Malinowski
Journal:  Pathol Oncol Res       Date:  2015-09-19       Impact factor: 3.201

8.  Endometrial cancer outcomes among non-Hispanic US born and Caribbean born black women.

Authors:  Matthew Schlumbrecht; Marilyn Huang; Judith Hurley; Sophia George
Journal:  Int J Gynecol Cancer       Date:  2019-05-03       Impact factor: 3.437

Review 9.  PARP Inhibitors in Gynecologic Cancers: What Is the Next Big Development?

Authors:  Michelle Lightfoot; Lauren Montemorano; Kristin Bixel
Journal:  Curr Oncol Rep       Date:  2020-02-17       Impact factor: 5.075

10.  Interleukin-11 in endometrial adenocarcinoma is regulated by prostaglandin F2alpha-F-prostanoid receptor interaction via the calcium-calcineurin-nuclear factor of activated T cells pathway and negatively regulated by the regulator of calcineurin-1.

Authors:  Kurt J Sales; Vivien Grant; Ian H Cook; David Maldonado-Pérez; Richard A Anderson; Alistair R W Williams; Henry N Jabbour
Journal:  Am J Pathol       Date:  2009-12-11       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.